Correct usage and dose adjustment principles of margetuximab

Margetuximab (Margetuximab) is a monoclonal antibody targeting HER2. It is mainly used to treat HER2-positive advanced or metastatic breast cancer, especially in patients who have received multiple anti-HER2 therapies but still experience disease progression. According to the recommended clinical dose, the standard dosage of margituximab is 15 mg/kg, administered by intravenous infusion, once every 3 weeks. The first infusion time is generally 120 minutes. If the patient tolerates it well, subsequent infusions can be shortened to 30 to 60 minutes.

During the course of medication, the patient's condition, tolerance and adverse reactions may require dosage adjustment. For example, if a patient experiences grade 3 or more serious adverse reactions (such as severe infusion reactions, abnormal cardiac function, etc.), the infusion should be suspended and appropriate supportive treatment should be provided. If symptoms resolve, doctors may consider reducing the dose or resuming treatment, but if the patient develops severe cardiotoxicity (such as a significant decrease in ejection fraction), permanent discontinuation is usually recommended. In addition, if the patient experiences severe infusion reactions (such as hyperthermia, hypotension, or allergic reactions) during treatment, the infusion rate may need to be slowed down or pretreatment with anti-allergic drugs may be required.

Margetuximab is often used in combination with chemotherapy (such as paclitaxel). Therefore, when formulating a treatment plan, doctors will adjust the dosing strategy based on the patient's overall health and tolerance to chemotherapy. For example, in patients who are elderly, frail or have existing heart disease, cardiac function may need to be monitored more closely and dosing frequency or dosage adjusted accordingly. In addition, patients should undergo regular cardiac ultrasound examinations to monitor left ventricular ejection fraction (LVEF) to ensure stable heart function.

In general, the use of margetuximab needs to strictly follow the doctor's instructions, and the dose should be adjusted in a timely manner according to individual tolerance. During the period of treatment, patients should closely monitor cardiac function, infusion-related reactions and laboratory indicators. If there are serious adverse reactions, they should communicate with the doctor in a timely manner to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.margenza.com/